NEW YORK, NY / ACCESSWIRE / July 29, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Sunlands Technology Group (NYSE: STG)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sunlands-technology-group-loss-submission-form?prid=2665&wire=1
Lead Plaintiff Deadline: August 26, 2019
Class Period: shareholders of Sunlands Technology Group who purchased shares pursuant and/or traceable to Sunlands’ March 2018 initial public stock offering.
Allegations against STG include that: (1) Sunlands’ student enrollment was declining; (2) Sunlands’ gross billings were declining; (3) Sunlands' marketing tactics were not as robust as described in the Registration Statement; and (4) as a result, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Ra Medical Systems, Inc. (NYSE: RMED)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ra-medical-systems-inc-loss-submission-form?prid=2665&wire=1
Lead Plaintiff Deadline: August 6, 2019
Class Period: stockholders that purchased Ra Medical securities pursuant and/or traceable to the Company’s September 2018 initial public offering.
Allegations against RMED include that: (1) the Company’s evaluation of sales personnel candidates was inadequate; (2) the Company’s training program for sales personnel was inadequate; (3) as a result, the Company could not reasonably assure that its newly hired sales personnel were adequately experienced; (4) as a result, the Company would suffer a shortage of qualified sales personnel; (5) the Company’s manufacturing process could not reasonably support increased catheter production; (6) as a result, the Company would suffer production delays; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Mallinckrodt Public Limited Company (NYSE: MNK)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/mallinckrodt-public-limited-company-loss-submission-form?prid=2665&wire=1
Lead Plaintiff Deadline: September 24, 2019
Class Period: February 28, 2018 to July 16, 2019
Allegations against MNK include that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong